Ipsen scuttles liver disease candidates from $952M Albireo acquisition
Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entire...
Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely.